Results 341 to 350 of about 145,800 (401)
Some of the next articles are maybe not open access.
Drugs, 2009
*Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M(3) receptors and blocking acetylcholinergic activation. *The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-
Claudine M Baldwin, Gillian M. Keating
openaire +3 more sources
*Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M(3) receptors and blocking acetylcholinergic activation. *The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-
Claudine M Baldwin, Gillian M. Keating
openaire +3 more sources
Drugs, 2009
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive diffusion) for up to 7 days. In a large phase III trial in cancer patients receiving multi-day (
Sean T. Duggan, Monique P Curran
openaire +3 more sources
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive diffusion) for up to 7 days. In a large phase III trial in cancer patients receiving multi-day (
Sean T. Duggan, Monique P Curran
openaire +3 more sources
Drug Discovery Today, 2004
Historically, developments in transdermal drug delivery have been incremental, focusing on overcoming problems associated with the barrier properties of the skin, reducing skin irritation rates and improving the aesthetics associated with passive patch systems.
Beverley J. Thomas, Barrie C. Finnin
openaire +3 more sources
Historically, developments in transdermal drug delivery have been incremental, focusing on overcoming problems associated with the barrier properties of the skin, reducing skin irritation rates and improving the aesthetics associated with passive patch systems.
Beverley J. Thomas, Barrie C. Finnin
openaire +3 more sources
Drugs of Today, 2007
Although older monoamine oxidase inhibitors (MAOIs) are effective in the treatment of depressive disorders, they are underutilized in clinical practice due to main concerns about interaction with tyramine-containing food, and side effects. Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called ...
Ashwin A, Patkar +2 more
openaire +2 more sources
Although older monoamine oxidase inhibitors (MAOIs) are effective in the treatment of depressive disorders, they are underutilized in clinical practice due to main concerns about interaction with tyramine-containing food, and side effects. Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called ...
Ashwin A, Patkar +2 more
openaire +2 more sources
Transdermal Electrochemical Monitoring of Glucose via High‐Density Silicon Microneedle Array Patch
Advanced Functional Materials, 2021Current technology for blood glucose level monitoring is mainly based on the invasive finger‐prick extraction of a small drop of blood using a lancet and measured via a handheld glucometer, which is not conducive to continuous measurements.
Muamer Dervisevic +6 more
semanticscholar +1 more source
Permeation enhancers in transdermal drug delivery: benefits and limitations
Expert Opinion on Drug Delivery, 2020Introduction: Transdermal drug delivery has several clinical benefits over conventional routes of drug administration. To open the transdermal route for a wider range of drugs, including macromolecules, numerous physical and chemical techniques to ...
Andrej Kováčik +2 more
semanticscholar +1 more source
2014
Many pain sufferers have difficultly using oral dosages or injections of medications, bringing about the need for an alternative means of delivery for both over the counter and prescription medications. A promising option is medicated patches that can transfer pain relieving drugs through the skin to a localized area.
Gradisher, Logan, Stephens, Analisa
openaire +1 more source
Many pain sufferers have difficultly using oral dosages or injections of medications, bringing about the need for an alternative means of delivery for both over the counter and prescription medications. A promising option is medicated patches that can transfer pain relieving drugs through the skin to a localized area.
Gradisher, Logan, Stephens, Analisa
openaire +1 more source
Drugs, 2003
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Seminars in Reproductive Medicine, 2001
This review summarizes the clinical studies involving the once-weekly Ortho Evra/Evra contraceptive patch. The patch delivers norelgestromin (NGMN), 150 microg, and ethinyl estradiol (EE), 20 microg, daily to the systemic circulation. The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 ...
G W, Creasy, L S, Abrams, A C, Fisher
openaire +2 more sources
This review summarizes the clinical studies involving the once-weekly Ortho Evra/Evra contraceptive patch. The patch delivers norelgestromin (NGMN), 150 microg, and ethinyl estradiol (EE), 20 microg, daily to the systemic circulation. The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 ...
G W, Creasy, L S, Abrams, A C, Fisher
openaire +2 more sources
Expert Opinion on Drug Delivery, 2005
Iontophoresis is a technique used to enhance the transdermal delivery of compounds through the skin via the application of a small electric current. By the process of electromigration and electro-osmosis, iontophoresis increases the permeation of charged and neutral compounds, and offers the option for programmed drug delivery.
Priya, Batheja +5 more
openaire +2 more sources
Iontophoresis is a technique used to enhance the transdermal delivery of compounds through the skin via the application of a small electric current. By the process of electromigration and electro-osmosis, iontophoresis increases the permeation of charged and neutral compounds, and offers the option for programmed drug delivery.
Priya, Batheja +5 more
openaire +2 more sources